SG147414A1 - Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias - Google Patents

Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias

Info

Publication number
SG147414A1
SG147414A1 SG200807427-0A SG2008074270A SG147414A1 SG 147414 A1 SG147414 A1 SG 147414A1 SG 2008074270 A SG2008074270 A SG 2008074270A SG 147414 A1 SG147414 A1 SG 147414A1
Authority
SG
Singapore
Prior art keywords
methods
preventing exercise
treating
preventing
induced
Prior art date
Application number
SG200807427-0A
Other languages
English (en)
Inventor
Andrew Robert Marks
Donald W Landry
Shi Xian Deng
Zhen Zhuang Cheng
Original Assignee
Univ Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Columbia filed Critical Univ Columbia
Publication of SG147414A1 publication Critical patent/SG147414A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5076—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving cell organelles, e.g. Golgi complex, endoplasmic reticulum
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/326—Arrhythmias, e.g. ventricular fibrillation, tachycardia, atrioventricular block, torsade de pointes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
SG200807427-0A 2003-10-07 2004-10-04 Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias SG147414A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/680,988 US20040229781A1 (en) 2000-05-10 2003-10-07 Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias

Publications (1)

Publication Number Publication Date
SG147414A1 true SG147414A1 (en) 2008-11-28

Family

ID=34465444

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200807427-0A SG147414A1 (en) 2003-10-07 2004-10-04 Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias

Country Status (14)

Country Link
US (1) US20040229781A1 (fr)
EP (1) EP1684735A4 (fr)
JP (1) JP2007507536A (fr)
KR (1) KR20060110290A (fr)
CN (1) CN100502845C (fr)
AU (1) AU2004281672A1 (fr)
BR (1) BRPI0415434A (fr)
CA (1) CA2541847A1 (fr)
EA (1) EA011357B1 (fr)
MA (1) MA28146A1 (fr)
NO (1) NO20062063L (fr)
SG (1) SG147414A1 (fr)
WO (1) WO2005037195A2 (fr)
ZA (1) ZA200603593B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7879840B2 (en) 2005-08-25 2011-02-01 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US8022058B2 (en) 2000-05-10 2011-09-20 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7718644B2 (en) * 2004-01-22 2010-05-18 The Trustees Of Columbia University In The City Of New York Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
US8710045B2 (en) 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors
KR20070072867A (ko) * 2004-09-01 2007-07-06 넥스메드 홀딩스 인코포레이티드 경피성 항구토 전달 시스템, 이의 방법 및 조성물
US7704990B2 (en) * 2005-08-25 2010-04-27 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
WO2008140592A2 (fr) * 2006-11-29 2008-11-20 Armgo Pharma, Inc. 1,4-benzothiazépines radioactivement marquées et procédés de criblage de composés qui lient les récepteurs de la ryanodine
DK2250159T3 (da) 2008-03-03 2012-03-19 Servier Lab Fremgangsmåde til fremstilling af benzothiazepiner fra gamma-amino-alkylbenzener
US8933129B2 (en) 2009-04-15 2015-01-13 State Of Oregon By And Through The State Board Of Higher Education On Behalf Of Portland State University Compounds and methods for modulating activity of calcium release channels
EP2708535A1 (fr) * 2012-05-11 2014-03-19 Les Laboratoires Servier Agents pour le traitement de troubles impliquant la modulation de récepteurs de la ryanodine
ES2643856B1 (es) 2016-05-24 2018-08-03 Universidad Del Pais Vasco / Euskal Herriko Unibertsitatea Triazoles para la regulación de la homeostasis de calcio intracelular
IL312745A (en) * 2021-11-16 2024-07-01 Armgo Pharma Inc Therapeutic compounds

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1060786A (en) * 1963-10-09 1967-03-08 Wander Ag Dr A Process for the preparation of lactams
DE3561317D1 (en) * 1984-01-27 1988-02-11 Ajinomoto Kk Manufacture of heptanoic acid derivatives
US4841055A (en) * 1985-03-25 1989-06-20 Japan Tobacco Inc. Desmosine derivatives and reagent for preparing artificial antigens
US4723012A (en) * 1985-03-25 1988-02-02 Japan Tobacco Inc. Desmosine derivatives having a disulfide bond and preparation of artificial antigen using the same
US6956032B1 (en) * 1986-04-18 2005-10-18 Carnegie Mellon University Cyanine dyes as labeling reagents for detection of biological and other materials by luminescence methods
US5124056A (en) * 1987-07-24 1992-06-23 Exxon Chemical Patents Inc. Polymer substituted amido-amine Mannich Base lubricant dispersant additives
JPS6445706A (en) * 1987-08-17 1989-02-20 Sumitomo Electric Industries Production of composite carbon nitride
US5210266A (en) * 1987-12-03 1993-05-11 Dainippon Pharmaceutical Co., Ltd. N-substituted mercaptopropanamide derivatives
DE58901634D1 (de) * 1988-11-05 1992-07-16 Bayer Ag Verfahren zur kernchlorierung von aromatischen kohlenwasserstoffen.
US5223508A (en) * 1988-12-27 1993-06-29 Kirin Beer Kabushiki Kaisha Pyridyl carboximidamide compounds useful in treating blood pressure
WO1991004654A1 (fr) * 1989-09-30 1991-04-18 Kirin Beer Kabushiki Kaisha Procede de production de plants
KR940000166B1 (ko) * 1989-11-09 1994-01-08 니혼다바고 상교오 가부시기가이샤 신규 글루코사민 유도체 및 이것을 막 구성성분으로서 함유한 리포솜
US5204462A (en) * 1990-03-30 1993-04-20 Japan Tobacco, Inc. 4h-3,1-benzoxazin-4-one derivative
US5517652A (en) * 1990-05-30 1996-05-14 Hitachi, Ltd. Multi-media server for treating multi-media information and communication system empolying the multi-media server
JP2651043B2 (ja) * 1990-07-10 1997-09-10 麒麟麦酒株式会社 ジフェニルメチルピペラジン誘導体
JP2703408B2 (ja) * 1990-12-28 1998-01-26 麒麟麦酒株式会社 １，４‐ベンゾチアゼピン誘導体
DE4102103A1 (de) * 1991-01-25 1992-08-20 Bayer Ag Substituierte benzoxazepine und benzthiazepine, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln
US5182272A (en) * 1991-05-03 1993-01-26 G. D. Searle & Co. 8-substituted-dibenz[b,f][1,4]oxazepine-10(11)-carboxylic acid, substituted hydrazides, pharmaceutical compositions, and methods for treating pain
US5180720A (en) * 1991-05-03 1993-01-19 G. D. Searle & Co. 2- and 3-alkoxy or hydroxy-8-substituted-dibenz[b,f]-[1,4]oxazepine-10(11H)-carboxylic acid, substituted hydrazides and methods for treating pain
US5593988A (en) * 1991-10-11 1997-01-14 Yoshitomi Pharmaceutical Industries, Ltd. Therapeutic agent for osteoporosis and diazepine compound
WO1993013082A1 (fr) * 1991-12-20 1993-07-08 G.D. Searle & Co. Dibenzoxazepines ou dibenzothiazepines substituees et utilisation desdites substances en tant qu'antagonistes des prostaglandines e¿2?
MX9300433A (es) * 1992-01-28 1994-07-29 Kirin Brewery Compuestos de piridincarboximidamina y composiciones farmaceuticas que los contienen.
GB9203347D0 (en) * 1992-02-17 1992-04-01 Wellcome Found Hypolipidaemic compounds
US5387684A (en) * 1992-03-25 1995-02-07 The Green Cross Corporation Isoindazole compound
US5304644A (en) * 1992-04-15 1994-04-19 G. D. Searle & Co. 1-,2-,3-,4-,5-,6-,7-,8- and/or 9 substituted dibenzoxazepine compounds, pharmaceutical compositions and methods for treating pain
US5523410A (en) * 1992-07-02 1996-06-04 Fujisawa Pharmaceutical Co., Ltd. Intermediate for synthesis and production of amino acid derivative
WO1994004523A1 (fr) * 1992-08-21 1994-03-03 Japan Tobacco Inc. Compose dioxacycloalcane a activite inhibitrice de la renine
PL179401B1 (pl) * 1992-11-09 2000-08-31 Boots Co Plc Nowe zwiazki, pochodne benzotioazepiny, sposób ich otrzymywania oraz kompozycja farmaceutyczna zawierajaca pochodne benzotioazepiny PL PL PL PL PL PL PL PL
ZA941003B (en) * 1993-02-15 1995-08-14 Wellcome Found Hypolipidaemic compounds
CA2153498A1 (fr) * 1993-11-10 1995-05-18 Hidetsura Cho Derive de chromanne et utilisation therapeutique de ce dernier
JPH08127594A (ja) * 1993-11-10 1996-05-21 Mochida Pharmaceut Co Ltd Ｆａｓ抗原に結合する新規蛋白質およびそれをコードするＤＮＡ
US6897295B1 (en) * 1993-11-10 2005-05-24 Mochida Pharmaceutical Co., Ltd. Antibodies and fragments thereof to Fas ligand and Fas ligand derived polypeptides
JP3914272B2 (ja) * 1993-12-28 2007-05-16 中外製薬株式会社 アドゼベリンをコードする遺伝子
JP2706755B2 (ja) * 1994-02-10 1998-01-28 日本たばこ産業株式会社 新規なベンジルアミノエトキシベンゼン誘導体
DE69535865D1 (de) * 1994-06-15 2008-11-27 Kirin Brewery Transferase und Amylase, Verfahren zur Herstellung dieser Enzyme, ihre Verwendung und kodierende Gene
US6632976B1 (en) * 1995-08-29 2003-10-14 Kirin Beer Kabushiki Kaisha Chimeric mice that are produced by microcell mediated chromosome transfer and that retain a human antibody gene
JP3193301B2 (ja) * 1995-09-14 2001-07-30 麒麟麦酒株式会社 生理活性タンパク質ｐ１６０
US5906819A (en) * 1995-11-20 1999-05-25 Kirin Beer Kabushiki Kaisha Rho target protein Rho-kinase
US5866341A (en) * 1996-04-03 1999-02-02 Chugai Pharmaceutical Co., Ltd. Compositions and methods for screening drug libraries
KR100771092B1 (ko) * 1996-07-08 2007-10-30 기린 파마 가부시끼가이샤 칼슘 수용체 활성 화합물
US5785178A (en) * 1996-11-04 1998-07-28 Minnesota Mining And Manufacturing Co. Packaged photocurable composition
CN1273586C (zh) * 1996-12-12 2006-09-06 麒麟麦酒株式会社 β1→4N－乙酰葡糖胺基转移酶和编码该酶的基因
TW555562B (en) * 1996-12-27 2003-10-01 Kirin Brewery Method for activation of human antigen-presenting cells, activated human antigen-presenting cells and use thereof
JP2894445B2 (ja) * 1997-02-12 1999-05-24 日本たばこ産業株式会社 Ｃｅｔｐ活性阻害剤として有効な化合物
US7112655B1 (en) * 1997-02-27 2006-09-26 Japan Tobacco, Inc. JTT-1 protein and methods of inhibiting lymphocyte activation
JP3521382B2 (ja) * 1997-02-27 2004-04-19 日本たばこ産業株式会社 細胞間接着及びシグナル伝達を媒介する細胞表面分子
WO1999018435A1 (fr) * 1997-10-08 1999-04-15 International Reagents Corporation Procede d'analyse de l'annexine v dans l'urine et utilisation
JP2959765B2 (ja) * 1997-12-12 1999-10-06 日本たばこ産業株式会社 ３−ピペリジル−４−オキソキナゾリン誘導体及びそれを含有してなる医薬組成物
EP1043335A4 (fr) * 1997-12-25 2005-08-31 Japan Tobacco Inc Anticorps monoclonal contre le facteur de croissance du tissu conjonctif et ses mises en applications medicales
US6410561B1 (en) * 1998-03-26 2002-06-25 Japan Tobacco Inc. Amide derivatives and nociceptin antagonists
AR015269A1 (es) * 1998-04-10 2001-04-18 Japan Tobacco Inc Compuesto amidinico y composicion farmaceutica, inhibidor de la coagulacion sanguinea e inhibidor del factor xa que lo comprenden
EP1085890A1 (fr) * 1998-06-08 2001-03-28 Advanced Medicine, Inc. Nouveaux medicaments des canaux sodiques et utilisations
EP1122311A4 (fr) * 1998-07-31 2002-04-17 Kirin Brewery Medicaments permettant de soigner la neuropathie contenant de la galectine-1 ou ses derives comme substance active
EP1147772B1 (fr) * 1998-12-28 2006-01-04 Noboru Kaneko utilisation de derivées 1,4-benzothiazepines pour la preparation d'un medicament dans LE TRAITEMENT DE LA FIBRILLATION atriale
AU754808B2 (en) * 1999-03-30 2002-11-28 Amgen Fremont Inc. Method for preparing Monoclonal Antibody
WO2001016321A1 (fr) * 1999-09-01 2001-03-08 Otsuka Pharmaceutical Co., Ltd. Adn et sequences proteiniques de glycoproteine vi (gpvi) de membranes plaquettaires et utilisations de ceux-ci
DE60032620T2 (de) * 1999-09-30 2007-10-04 Kaneko, Noboru Antikrebsmittel
US6568474B2 (en) * 1999-12-20 2003-05-27 Bj Services, Usa Rigless one-trip perforation and gravel pack system and method
DE60015392D1 (de) * 1999-12-29 2004-12-02 Glaxo Group Ltd Verwendung von annexin-modulatoren zur herstellung eines medikaments zur behandlung und/oder vorbeugung von arthritis und arthritischen erkrankungen
NZ519981A (en) * 2000-01-20 2005-02-25 Eisai Co Ltd Nitrogenous cyclic compounds and pharmaceutical compositions containing the same
US6545170B2 (en) * 2000-04-13 2003-04-08 Pharmacia Corporation 2-amino-5, 6 heptenoic acid derivatives useful as nitric oxide synthase inhibitors
DE60119723T2 (de) * 2000-05-03 2007-04-26 Astellas Pharma Inc. Pharmazeutische zusammensetzung enthaltend furosemid und conivaptan zur behandlung des kongestiven herzversagens
US20040048780A1 (en) * 2000-05-10 2004-03-11 The Trustees Of Columbia University In The City Of New York Method for treating and preventing cardiac arrhythmia
US6489125B1 (en) * 2000-05-10 2002-12-03 The Trustees Of Columbia University In The City Of New York Methods for identifying chemical compounds that inhibit dissociation of FKBP12.6 binding protein from type 2 ryanodine receptor
WO2002009761A2 (fr) * 2000-07-27 2002-02-07 Pharmacia Corporation Polytherapie par antagoniste d'aldosterone epoxy-steroidien et inhibiteur calcique pour le traitement de l'insuffisance cardiaque congestive
AR031129A1 (es) * 2000-09-15 2003-09-10 Pharmacia Corp Derivados de los acidos 2-amino-2-alquil-4-hexenoico y -hexinoico utiles como inhibidores de oxido nitrico sintetasa
TWI290130B (en) * 2000-09-15 2007-11-21 Pharmacia Corp 2-Amino-2alkyl-5 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors
EP1916303B1 (fr) * 2000-11-30 2013-02-27 Medarex, Inc. Acides nucléiques codant des séquences d'immunoglobulines humaines réarrangées obtenus de souris transgéniques chromosomales
US6673904B2 (en) * 2000-12-23 2004-01-06 Kirin Beer Kabushiki Kaisha Stem cell growth factor-like polypeptides
CA2437021A1 (fr) * 2001-02-01 2002-08-08 Mochida Pharmaceutical Co., Ltd. Proteine associee a l'adiponectine
JP4817514B2 (ja) * 2001-03-09 2011-11-16 協和発酵キリン株式会社 新規動物細胞用ベクターおよびその使用
WO2002072145A1 (fr) * 2001-03-14 2002-09-19 Ono Pharmaceutical Co., Ltd. Remedes antidepresseurs contenant un antagoniste ep1 en tant que principe actif
US20030054531A1 (en) * 2001-03-19 2003-03-20 Decode Genetics Ehf, Human stroke gene
DE60226912D1 (de) * 2001-04-27 2008-07-10 Kirin Pharma K K Chinolin- und Chianzolinderivate zur Behandlung von Tumoren
JP4269052B2 (ja) * 2001-09-14 2009-05-27 アムジエン・インコーポレーテツド 連結ビアリール化合物
JP2003145746A (ja) * 2001-11-16 2003-05-21 Seiko Epson Corp インクジェット記録方法及びインクジェット記録装置
US20060100195A1 (en) * 2001-11-19 2006-05-11 Takayuki Maruyama Remedies for urinary frequency
CA2469228A1 (fr) * 2001-12-03 2003-06-12 Japan Tobacco Inc. Compose azole et utilisation medicinale de celui-ci
CA2471639A1 (fr) * 2002-01-17 2003-07-31 Pharmacia Corporation Nouveaux composes d'alkyl/aryl hydroxy ou cetothiepine servant d'inhibiteurs du transport des acides biliaires de type ileal et de l'absorption de taurocholate
AU2003227433A1 (en) * 2002-04-26 2003-11-10 Japan Tobacco Inc. Bar-like article forming device
JP4113042B2 (ja) * 2002-05-24 2008-07-02 シチズンホールディングス株式会社 表示装置およびカラー表示方法
BR0306208A (pt) * 2002-08-30 2004-10-13 Japan Tobacco Inc Compostos de dibenzilamina e seu uso farmacêutico
US20050032210A1 (en) * 2003-03-18 2005-02-10 Kirin Beer Kabushiki Kaisha Method of preparing immuno-regulatory dendritic cells and the use thereof
US20050009733A1 (en) * 2003-04-22 2005-01-13 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a potassium ion channel modulator for the treatment of central nervous system damage
TWI393560B (zh) * 2003-05-02 2013-04-21 Japan Tobacco Inc 包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
WO2005016249A2 (fr) * 2003-07-11 2005-02-24 Pharmacia Corporation Compositions constituees d'un inhibiteur chromene ou acide phenylacetique selectif de la cyclooxygenase-2 et d'un inhibiteur de ace pour traiter les lesions du systeme nerveux central
JP2007501801A (ja) * 2003-08-07 2007-02-01 日本たばこ産業株式会社 ピロロ［１，２−ｂ］ピリダジン誘導体
US20070010571A1 (en) * 2003-08-20 2007-01-11 Nitromed, Inc. Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use
WO2005023183A2 (fr) * 2003-08-28 2005-03-17 Nitromed, Inc. Composes diuretiques nitroses et nitrosyles, compositions et procedes d'utilisation correspondants
WO2005104835A2 (fr) * 2004-04-22 2005-11-10 Kirin Beer Kabushiki Kaisha Animaux transgeniques et leurs utilisations
US7378423B2 (en) * 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
JP3968358B2 (ja) * 2004-06-30 2007-08-29 日本電信電話株式会社 薄型フラットツイストぺアすきまケーブル及びすきまナビゲータユニット
RU2392278C2 (ru) * 2004-07-15 2010-06-20 Джапан Тобакко Инк. Конденсированное производное бензамида и ингибитор активности подтипа 1 рецептора ваниллоида (vr1)
AR051780A1 (es) * 2004-11-29 2007-02-07 Japan Tobacco Inc Compuestos en anillo fusionados que contienen nitrogeno y utilizacion de los mismos
US7704990B2 (en) * 2005-08-25 2010-04-27 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors

Also Published As

Publication number Publication date
KR20060110290A (ko) 2006-10-24
EA011357B1 (ru) 2009-02-27
EP1684735A2 (fr) 2006-08-02
BRPI0415434A (pt) 2006-12-05
WO2005037195A3 (fr) 2005-12-01
CN100502845C (zh) 2009-06-24
AU2004281672A1 (en) 2005-04-28
CN1886122A (zh) 2006-12-27
NO20062063L (no) 2006-07-07
ZA200603593B (en) 2010-10-27
EA200600740A1 (ru) 2006-10-27
US20040229781A1 (en) 2004-11-18
WO2005037195A2 (fr) 2005-04-28
CA2541847A1 (fr) 2005-04-28
MA28146A1 (fr) 2006-09-01
EP1684735A4 (fr) 2009-01-07
JP2007507536A (ja) 2007-03-29

Similar Documents

Publication Publication Date Title
NO20062063L (no) Forbindelser og fremgangsmater for behandling og forbyggelse av treningsinduserte hjerte arrytmier
MY134783A (en) Rho-kinase inhibitors
MY142915A (en) Rho-kinase inhibitors
GB0318447D0 (en) Therapeutic agents
GB0225475D0 (en) Therapeutic agents
DE60332137D1 (en) Cyclohexyl-sulphone als gamma-sekretase-inhibitoren
GB0225474D0 (en) Therapeutic agents
TW200510405A (en) Bridged n-arylsulfonylpiperidines as gamma-secretase inhibitors
SI3072978T1 (sl) 1L1RL-1 kot marker za kardiovaskularne bolezni
EP1583750A4 (fr) Inhibiteurs de beta-secretase macrocyclique pour traiter la maladie d'alzheimer
ATE311206T1 (de) Substituierte porphyrine
EA200702057A1 (ru) Новые антиаритмические и применяемые при сердечной недостаточности лекарственные средства, которые направлены против "просачивания" рецептора рианодина (ryr2)
BR0007720A (pt) Porfirinas substituìdas
WO2004043954A3 (fr) Trans-9,10-dehydroepothilones c et d, leurs analogues et leurs procedes de production
BG106020A (en) Inhibitors of impdh enzyme
MY135477A (en) 2-(2,6-dichlorophenyl)-diarylimidazoles
ATE354563T1 (de) Sulfonderivate zur hemmung von gamma-secretase
EP1656359A4 (fr) Inhibiteurs macrocycliques de la beta-secretase destines au traitement de la maladie d'alzheimer
MXPA05004247A (es) Cromonas y derivados de cromona y usos de los mismos.
WO2001058476A3 (fr) Procedes et compositions pour le traitement de la maladie d'alzheimer par le renforcement de l'activite de la plasmine ou de l'activite du type de la plasmine
MXPA06000138A (es) Metodos para tratar y evitar la arritmia cardiaca.
BG106293A (en) Method of inhibiting amyloid protein aggregation and imaging amyloid deposits
BG105710A (en) 5ht1 antagonists for antidepressant therapy
DE602004006118D1 (de) 2,3,4,5-TETRAHYDROBENZOiFöi1,4öOXAZEPIN-5-CARBONSÄUREAMID DERIVATE ALS GAMMA-SECRETASE INHIBITOREN ZUR BEHANDLUNG VON ALZHEIMER
CA2534489A1 (fr) Inhibiteurs de la cathepsine s